Exelixis Analyst Price Targets

Wall Street analyst price targets and consensus rating for Exelixis (EXEL).

Price Target Range — 9 Quarters

Analyst Consensus — 17 Analysts

2S.Buy

8Buy

7Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$49Upside to Avg. PT-26.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Citizens	Silvan Turkcan	PT Raise	Market Outperform	$55→$65
Oct 9, 2026	RBC Capital	Leonid Timashev	PT Raise	Sector Perform	$45→$51
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Sector Perform	$46→$45
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Hold	$52→$54
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Market Perform	$54
Aug 6, 2026	Truist Securities	Gregory Renza	PT Cut	Hold	$56→$52
Aug 6, 2026	Stifel	Stephen Willey	PT Raise	Hold	$47→$51
Jul 23, 2026	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$50→$53
Jul 14, 2026	Barclays	Etzer Darout	PT Raise	Equal-Weight	$45→$49
Jul 13, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$40→$49
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Raise	Sector Perform	$43→$46
Jul 7, 2026	Truist Securities	Gregory Renza	PT Raise	Hold	$54→$56
Jul 2, 2026	UBS	Ashwani Verma	PT Raise	Neutral	$43→$52
Jul 2, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$56
Jun 25, 2026	Truist Securities	Gregory Renza	Downgrade	Buy→Hold	$51→$54
Jun 24, 2026	Citizens	Silvan Turkcan	PT Raise	Market Outperform	$50→$55
May 7, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$54→$56
May 6, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$51→$55
May 6, 2026	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$49→$50
May 6, 2026	Stifel	Stephen Willey	PT Raise	Hold	$44→$47

Analyst Ratings News

PRO
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65

Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and raises the price target from $55 to $65.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $45 to $51.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and lowers the price target from $46 to $45.

Benzinga Newsdesk

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.

Vandana Singh

PRO
BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54

BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and announces Price Target of $54.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52

Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and lowers the price target from $56 to $52.

Benzinga Newsdesk

Exelixis Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Exelixis Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65

PRO
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51

PRO
RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

PRO
BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54

PRO
Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52

People Also Watch

People Also Watch

Exelixis Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Exelixis Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Maintains Market Outperform on Exelixis, Raises Price Target to $65

PRORBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51

PRORBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

PROBMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54

PROTruist Securities Maintains Hold on Exelixis, Lowers Price Target to $52

People Also Watch

People Also Watch

PRO
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65

PRO
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51

PRO
RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45

PRO
BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54

PRO
Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52